Genprex (NASDAQ:GNPX) Trading 3.7% Higher

Genprex Inc (NASDAQ:GNPX) traded up 3.7% during mid-day trading on Monday . The stock traded as high as $0.29 and last traded at $0.28, 276,351 shares traded hands during mid-day trading. An increase of 107% from the average session volume of 133,604 shares. The stock had previously closed at $0.27.

The firm has a market cap of $4.28 million, a price-to-earnings ratio of -0.31 and a beta of 1.14. The firm’s 50-day moving average is $0.42 and its 200-day moving average is $0.92.

A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC acquired a new position in shares of Genprex Inc (NASDAQ:GNPX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned about 0.20% of Genprex at the end of the most recent reporting period. 12.62% of the stock is owned by institutional investors and hedge funds.

About Genprex (NASDAQ:GNPX)

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Read More: G-20

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.